UPMC will invest some of its recently announced $1bn healthcare commercialisation budget to create a new pharmaceutical development firm.

McKesson Ventures co-led the first round to be disclosed by the clinical trial services provider, which will put the money into recruitment and improving its technology platform.

Chalmers University of Technology-founded baby ventilation monitor developer Monivent will join the Spotlight Stock Market in an IPO where 60% of shares have advance subscriptions in place.

University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.

The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.

The UBC bioprinting spinout will use part of the funding to progress two of its projects towards commercialisation.

Utah-founded metagenomic evaluation platform developer IDbyDNA has now raised at least $29m, with the latest round to support continued commercialisation.

The Sanofi-backed cancer therapy developer is set to raise between $140m and $160m in its initial public offering following $226m in funding.

The CNS disorder-focused drug developer has filed to raise up to $125m having raised $226m in funding from backers including Eli Lilly and Access Industries.

The financial services provider aims to secure some 200 limited partners for a vehicle that will meld industry 4.0 technology with Japan's Society 5.0 initiative.